Porphycenes


  • Photosensitizer: Porphycenes
  • Tradename: ATMPn
  • Company Photosensitizer: Cytopharm and GlaxoWellcome Vim Rx
  • Clinical Application: Dermal applications (psoriasis, non-melanoma skin cancer)
  • Wavelength (nm): 630
  • Extinction Coefficient (M-1 cm-1): 5.2 104
  • Mode of Delivery: Topical
  • Delivery vehicle: Liposomal
  • Typical Dose (mg kg-1): 1.0–3.0
  • Light Dose (J cm-2): -
  • Time Post-Injection: n/a
  • Duration of Skin Photosensitivity: -

Glaxo Dermatology, a division of GlaxoWellcome (Research Triangle Park, NC, USA), along with Cytopharm (Menlo Park, CA, USA) have done extensive preclinical work using the porphycene ATMPn [9-acetoxy-2,7,12,17- tetrakis-(b-methoxyethyl)-porphycene][97].
The presence of its four b-methoxyethyl side-chains accelerates cellular uptake whilst the acetoxy-group increases the solubility and hydrophilicity of the molecule[97]. This compound can be applied topically, making it useful for dermal applications[69]. In vitro studies have shown that ATMPn has an unusually fast uptake into skin cells not seen for other second-generation photosensitizers and is undergoing preclinical testing against psoriasis vulgaris and superficial non-melanoma skin cancer.



Porphycenes

Index